Showing results (131-140 of 154) with videos related to
Sort By:
Pageof 16
Investigational New Drugs|August 26, 2016
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patientsTeresa Di Desidero, Lisa Derosa, Luca Galli, et al.The Journal of Clinical Endocrinology and Metabolism|December 15, 2010
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancerAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.Cancer Research|September 18, 2004
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodiesGuido Bocci, Shan Man, Shane K Green, et al.Journal of Medicinal Chemistry|January 23, 2014
Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studiesStefania Sartini, Vito Coviello, Agostino Bruno, et al.Journal of Medicinal Chemistry|June 16, 2016
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic ConditionsVito Coviello, Beatrice Marchi, Stefania Sartini, et al.Oncology Reports|March 9, 2018
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Poupak Fallahi, et al.Investigational New Drugs|October 2, 2017
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapyFrancesco Pasqualetti, Alessandra Gonnelli, Martina Cantarella, et al.Molecular and Cellular Endocrinology|June 17, 2014
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.European Journal of Medicinal Chemistry|August 31, 2015
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2Silvia Salerno, Anna Maria Marini, Giacomo Fornaciari, et al.Pageof 16